cancer researcH uk award adenovIrus
process development contract to tHe cbf
oxfoRd UnivERsity consUlting
Cancer Research UK has awarded the University of Oxford’s
Clinical BioManufacturing Facility (CBF) its first commercial
process development contract for the production of an
adenovirus vector, for use in treating patients with recurrent
ovarian cancer and hepatic metastases associated with
the cbf already possesses a distinguished history in the
production of biological products for use in medicine, in
particular, monoclonal antibodies and related biologics*.
originally known as the therapeutic Antibody centre (tAc),
the unit was a leading academic gMP (good Manufacturing
Practice) facility for the production of monoclonal antibodies
and part of the sir william dunn school of Pathology.
however, in november 2005 the unit became the cbf
and joined the nuffield department of clinical Medicine.
today the cbf’s focus is upon the challenges faced in the
production of viral vectors for use as novel recombinant
vaccines and for cancer therapy. its most notable recent
success has been in the production of their first vaccine for
the prevention of malaria, which is in Phase i clinical trials
at the centre for clinical vaccinology and tropical Medicine.
two novel vaccines against hepatitis c have full approval
from the Medicines and healthcare products Regulatory
Agency (MhRA), and are about to start Phase i clinical trials
cbf’s objective is to provide the link between academic
research and clinical drug development, thereby facilitating
the rapid progress of promising biologics into clinical trials.
A suite of clean rooms with supporting Qc (Quality control)
laboratories and a nominated Qualified Person enables the
production of master cell banks, master virus seed stocks
and clinical grade material. the cbf is unusual in that it also
offers a fill and finish service. it is therefore able to offer a
complete service, starting with dnA, and ending up wi